Ultrasound elastography is being proposed as a way to guide and monitor ablation therapy. Researchers say elastography could help ultrasound overcome limitations in this setting, and increase its visibility among other imaging modalities used for guidance.
Ultrasound elastography is being proposed as a way to guide and monitor ablation therapy. Researchers say elastography could help ultrasound overcome limitations in this setting, and increase its visibility among other imaging modalities used for guidance.
As the prevalence of liver cancer increases, physicians foresee a boom in utilization of radiofrequency and other thermal ablation procedures. Therefore, considerable procedural sophistication is needed. Ultrasound is one of the preferred imaging modalities for radiofrequency ablation guidance. However, the bubbling effect produced by thermal coagulation in tissue typically impairs sonographic visualization. Elastography helps overcome this problem by echoing tissue strain in the zone of necrosis, said Flemming Forsberg, Ph.D., a professor of radiology at Thomas Jefferson University in Philadelphia.
A research team led by James A. Zagzebski, Ph.D., and Tomy Varghese, ultrasound imaging experts in the medical physics department at the University of Wisconsin in Madison, recently unveiled results on an RFA-based technique called electrode displacement elastography. This method enhances lesion targeting by reducing sliding and motion of abdominal organs undergoing ablation. They presented their findings at the 2006 American Institute of Ultrasound in Medicine meeting in March.
"Elastographic ultrasound guidance should make procedures faster and you may get away with killing less tissue," Forsberg said. "There are still some lesions we don't see very well with ultrasound. But it becomes a trade-off when radiation is an issue. We are doing more and more ablation therapy these days. This means we could do more RFA with ultrasound that otherwise used to be performed with CT for guidance."
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.